Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer

Oncologist

Volumn 13, Issue SUPPL. 1, 2008, Pages 21-27

  Sekine, Ikuo ^a,b   Sumi, Minako ^b   Saijo, Nagahiro ^c  

^a Division of Internal Medicine and Thoracic Oncology   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Bone metastasis; Brain metastasis; Chemotherapy; Non small cell lung cancer; Pleural effusion

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; TENIPOSIDE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SYSTEMIC THERAPY; BONE TUMOR; BRAIN TUMOR; LUNG TUMOR; METASTASIS; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 42049112417     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.13-S1-21     Document Type: Review

References (44)

1. Wozniak A, Gadgeel S. Clinical presentation of non-small cell carcinoma of the lung. In: Pass H, Carbone D, Minna J et al., eds. Lung Cancer: Principles and Practice, Third Edition. Philadelphia: Lippincott Williams & Wilkins, 2005;291-303.
2. Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg 1995;170:69-74.
3. DeCamp MM Jr, Mentzer SJ, Swanson SJ et al. Malignant effusive disease of the pleura and pericardium. Chest 1997; 112(4 suppl): 291S-295S.
4. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: An assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117:73-78.
5. Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978;23:68-72.
6. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 2002;50:373-382.
7. Wagner T. [Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer.] Onkologie 1984;7:22-26. German.
8. Spira A, BrahmerJ. Effusions. In: Abeloff M, Armitage J, Niederhuber J et al., eds. Clinical Oncology, Third Edition. Philadelphia: Elsevier Churchill Livingstone, 2004;1179-1212.
9. Fujita A, Takabatake H, Tagaki S et al. Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer: Cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support. Chest 2001;119:340-343.
10. Kimura H, Fujiwara Y, Sone T et al. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 2006;95:1390-1395.
11. Tosoni A, Ermani M, Brandes AA. The pathogenesis and treatment of brain metastases: A comprehensive review. Crit Rev Oncol Hematol 2004;52:199-215.
12. Gavrilovic IT, Posner JB. Brain metastases: Epidemiology and pathophysiology. J Neurooncol 2005;75:5-14.
13. Nussbaum ES, Djalilian HR, Cho KH et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996;78:1781-1788.
14. van den Bent MJ. The role of chemotherapy in brain metastases. Eur J Cancer 2003;39:2114-2120.
15. Stewart DJ, Molepo JM, Green RM et al. Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer 1995;71:598-604.
16. Heimans JJ, Vermorken JB, Wolbers JG et al. Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 1994;5:951-953.
17. Minotti V, Crino L, Meacci ML et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 1998;20:93-98.
18. Crino L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17:3522-3530.
19. Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study. Cancer 1999;85:1599-1605.
20. Fujita A, Fukuoka S, Takabatake H et al. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 2000;59:291-295.
21. Robinet G, Thomas P, Breton JL et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol 2001;12:59-67.
22. Bernardo G, Cuzzoni Q, Strada MR et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: A phase II study. Cancer Invest 2002;20:293-302.
23. Cortes J, Rodriguez J, Aramendia JM et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 2003;64:28-35.
24. Katz A, Zalewski P. Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib. Br J Cancer 2003;89(suppl 2):S15-S18.
25. Grimm S, De Angelis L. Brain metastases. In: Kufw D, Bast R, Hait W et al., eds. Cancer Medicine, Seventh Edition. Hamilton, Canada: BC Decker Inc., 2006;1065-1070.
26. Coleman R, Rubens R. Bone metastases. In: Abeloff M, Armitage J, Niederhuber J et al., eds. Clinical Oncology, Third Edition. Philadelphia: Elsevier Churchill Livingstone, 2004:1091-1128.
27. Cherny N, Portenoy R. Cancer pain: Principles of assessment and syndromes. In: Wall P, Melzack R, eds. Textbook of Pain, Fourth Edition. Edinburgh, UK: Churchill Livingstone, 2002:1017-1064.
28. Galasko CS, Norris HE, Crank S. Spinal instability secondary to metastatic cancer. J Bone Joint Surg Am 2000;82:570-594.
29. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: A review. Crit Rev Oncol Hematol 2005;56:365-378.
30. van der Linden YM, Steenland E, van Houwelingen HC et al. Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: Results on survival in the Dutch Bone Metastasis Study. Radiother Oncol 2006;78:245-253.
31. Chow E, Fung K, Panzarella T et al. A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 2002;53:1291-1302.
32. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 1989;256-264.
33. Van der Linden YM, Dijkstra PD, Kroon HM et al. Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br 2004;86:566-573.
34. Prasad D, Schiff D. Malignant spinal-cord compression. Lancet Oncol 2005;6:15-24.
35. Loblaw DA, Laperriere NJ, Mackillop WJ. A population-based study of malignant spinal cord compression in Ontario. Clin Oncol (R Coll Radiol) 2003;15:211-217.
36. Kimura M, Tominaga T. Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer. Breast Cancer 2002;9:153-159.
37. Harvey HA. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma. Cancer 1997;80(8 suppl):1646-1651.
38. Vansteenkiste J, Vandebroek J, Nackaerts K et al. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: Detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer 2003;40:191-199.
39. Ellis PA, Smith IE, Hardy JR et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995;71:366-370.
40. Zhang XT. Li LY, Wang SL et al. Improvements in quality of life and disease-related symptoms in patients with advanced non-small cell lung cancer treated with gefitinib. Chin Med J(Engl) 2005;118:1661-1664.
41. Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327:469.
42. Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-3157.
43. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621.
44. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.